Overall verdict
Neutral
3.6/10
1-year performance
-9.06%
Score breakdown
Down 9.1% over 1 year, 10% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
5 analysts, target +2.9% vs the price.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau ; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand ; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
—
Founded
—
Employees
45
Revenue / employee
780 289 USD
Next earnings
November 9, 2026 (estimated)
Institutional holders
- MORGAN STANLEY9.21%
- FMR LLC8.10%
- Bain Capital Life Sciences Investors, LLC7.75%
- PERCEPTIVE ADVISORS LLC7.72%
- Saturn V Capital Management LP6.78%
- Deep Track Capital, LP5.72%
- BlackRock, Inc.5.40%
- Kalehua Capital Management LLC3.62%
- VANGUARD CAPITAL MANAGEMENT LLC3.62%
- Other institutions31.59%
- Rest of the register10.49%
86 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
4.83 USD
52-week low
2.80 USD
1-year performance
-9.06%
Declining
Year-to-date performance
-23.77%
Declining
Drawdown
-37.89%
Major drawdown
Position in the 52-week range
10% of range
Gross margin 80.8%, the company loses 568.8% of its revenue, ROIC -57.6%, ROE -113.1%.
Net margin
-568.80%
Negative
Sector -229.11%|S&P 12.97%
Gross margin
80.77%
Exceptional
Return on equity (ROE)
-113.08%
Negative
Sector -58.11%|S&P 16.52%
Return on invested capital (ROIC)
-57.63%
Negative
Free cash flow margin (FCF)
-528.40%
Negative
Revenue to net income
Growth
10.0/10Revenue up 346.3% over 1 year, 63.6% a year over 5.
Revenue (trailing 12 months)
15.8M USD
Revenue growth (1y)
346.33%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Market cap
308M USD
Financial strength
6.8/10Cash covers 270.1% of the debt, net debt/EBITDA 1.4x.
Net debt / EBITDA
1.4x
Solid
Gearing (net debt / equity)
-84.48%
Net cash
Cash
209M USD
Cash / market cap
67.63%
Very solid
Cash / total debt
270.06%
Net cash
Interest coverage
-10.1x
Stretched
Net debt
-131M USD
Equity
155M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 3.00 USD
- MM203.67
- MM503.91
- MM2003.93
- RSI 1425.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.17%
200-day average slope, 3 months
+4.05%
50-day average slope, 1 month
-4.14%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.05 % per day
Volatility change
-3.77%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.67 (5) | -0.67 (5) | 16 (5) | — | -87 (5) |
| 2027 | -0.72 (5) | -0.77 (4) | 12 (5) | — | -104 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 8, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 4 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 5 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 6 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 7 | XFOR | 3.6 | 3.0 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.4x | -27.2 % | -9.1 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
